Wearable biofeedback system improves balance in Parkinson’s patients

Researchers at the University of Houston in the Department of Health and Human Performance are hoping to improve quality of life for Parkinson’s patients with a wearable belt connected to a smartphone application to help users regain balance.

The Smarter Balance System (SBS) is a personalized wearable, smartphone-connected biofeedback rehabilitation system that guides patients though balance rehabilitation exercises. Using vibrating actuators, the system utilizes “touch guidance” to guide and map a patient’s movements in real-time that can be reviewed on a smartphone.

"The smartphone application records and creates a custom motion for their body tilt based on their individual limits of stability. The touch guidance from the vibrating actuators is almost acting as if a physical therapist is guiding them," said Alberto Fung, University of Houston graduate student and part of the Sensori-Motor Augmentation & Rehabilitation Technology (SMART) Research Group.

In a six week, at-home study, researchers noted users experienced noticeable improvements.

"Our overarching goal is to improve their quality of life by improving postural stability, reducing the number of falls and increasing their confidence in daily activities," said Beom-Chan Lee, assistant professor and principle investigator of the study, which is assessing the impacts of long-term rehabilitative training on patients using the SBS system developed by Lee's team. "It's important to develop a system that is easy to use and readily available in the home environment. Most of the time, patients have to rehab at a clinic but there might be limited access. We're not trying to replace traditional therapy but there is a shortage of physical therapists."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.